# 5AM Venture Management, LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1799883. Source: https://holderbook.com/funds/1799883-5am-venture-management-llc/

- Reported value: $287.9M
- Positions: 16
- Weight of the ten largest: 85.6%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| MAPLIGHT THERAPEUTICS INC | [MPLT](https://holderbook.com/stocks/MPLT/) | $34.0M | 950,011 | 11.8% | 3 |
| TYRA BIOSCIENCES INC | [TYRA](https://holderbook.com/stocks/TYRA/) | $32.9M | 1,029,298 | 11.4% | 12 |
| ENTRADA THERAPEUTICS INC | [TRDA](https://holderbook.com/stocks/TRDA/) | $29.9M | 4,056,379 | 10.4% | 19 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $27.6M | 797,600 | 9.6% | 17 |
| CAMP4 THERAPEUTICS CORP | [CAMP](https://holderbook.com/stocks/CAMP/) | $25.6M | 5,869,091 | 8.9% | 7 |
| ARTIVA BIOTHERAPEUTICS INC | [ARTV](https://holderbook.com/stocks/ARTV/) | $22.8M | 2,353,304 | 7.9% | 8 |
| TECTONIC THERAPEUTIC INC | [TECX](https://holderbook.com/stocks/TECX/) | $20.9M | 606,660 | 7.2% | 9 |
| ZENTALIS PHARMACEUTICALS INC | [ZNTL](https://holderbook.com/stocks/ZNTL/) | $19.1M | 3,947,913 | 6.7% | 13 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $18.5M | 497,270 | 6.4% | 13 |
| EYEPOINT INC | [EYPT](https://holderbook.com/stocks/EYPT/) | $15.0M | 1,050,000 | 5.2% | 9 |
| BIOHAVEN LTD | [BHVN](https://holderbook.com/stocks/BHVN/) | $11.0M | 738,972 | 3.8% | 11 |
| SURROZEN INC | [SRZN](https://holderbook.com/stocks/SRZN/) | $7.0M | 271,250 | 2.4% | 6 |
| SKYE BIOSCIENCE INC | [SKYE](https://holderbook.com/stocks/SKYE/) | $6.7M | 9,681,763 | 2.3% | 9 |
| ALX ONCOLOGY HLDGS INC | [ALXO](https://holderbook.com/stocks/ALXO/) | $6.3M | 3,057,325 | 2.2% | 2 |
| PROTARA THERAPEUTICS INC | [TARA](https://holderbook.com/stocks/TARA/) | $5.2M | 1,369,782 | 1.8% | 7 |
| SILENCE THERAPEUTICS PLC | [SLN](https://holderbook.com/stocks/SLN/) | $5.2M | 476,200 | 1.8% | 10 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +11.2% | +14.8% | -3.6% | 94% |
| Q1 2026 | +35.4% | -4.6% | +40.0% | 99% |
| Q4 2025 | +32.1% | +2.4% | +29.7% | 99% |
| Q3 2025 | +26.9% | +7.8% | +19.1% | 96% |
| Q2 2025 | +7.2% | +10.5% | -3.3% | 100% |
| Q1 2025 | -34.4% | -4.6% | -29.8% | 100% |
| Q4 2024 | -11.2% | +2.1% | -13.4% | 100% |
| Q3 2024 | +6.3% | +5.4% | +0.9% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $287.9M | 16 |
| Q1 2026 | $360.2M | 20 |
| Q4 2025 | $318.1M | 21 |
| Q3 2025 | $273.0M | 25 |
| Q2 2025 | $260.1M | 29 |
| Q1 2025 | $264.4M | 31 |
| Q4 2024 | $419.1M | 31 |
| Q3 2024 | $484.0M | 28 |
| Q2 2024 | $447.1M | 28 |
| Q1 2024 | $446.6M | 26 |
| Q4 2023 | $377.0M | 25 |
| Q3 2023 | $347.5M | 26 |